TY - JOUR
T1 - Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer
AU - Nakamura, Akira
AU - Akiyama, Kenichi
AU - Takai, Toshiyuki
N1 - Funding Information:
This work is supported by the CREST programme of Japan Science and Technology Agency, a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant of the Virtual Research Institute of ageing of Nippon Boehringer Ingelheim, a grant of the Mochida Memorial Foundation for Medical and Pharmaceutical Research, a grant of Kanzawa Medical Research Foundation, and a grant for the 21st century COE programme ‘Center for Innovative Therapeutic Development Towards the Conquest of Signal Transduction Diseases’.
PY - 2005/2
Y1 - 2005/2
N2 - Immune activation and inhibitory receptors play an important role in the maitenance of an adequate activation threshold of various cells in our immune system. Analyses of murine models show that the inhibitory Fc receptor, FcγRIIB plays an indispensable role in the suppression of antibody-mediated allergy and autoimmunity. In contrast, the activating-type Fc receptors (FcRs) are essential for the development of these diseases, suggesting that regulation of inhibitory or activating FcR is an ideal target as a therapeutic agent. In addition, recent crystal structural analyses of FcR-Ig-Fc fragment complexes provide an effective approach for developing FcR-targeting drugs. This review summarises recent advances of FcR, which were mainly obtained by murine studies, and highlights novel antibodies as possible FcR-targeting therapies for allergy, autoimmune diseases and cancer.
AB - Immune activation and inhibitory receptors play an important role in the maitenance of an adequate activation threshold of various cells in our immune system. Analyses of murine models show that the inhibitory Fc receptor, FcγRIIB plays an indispensable role in the suppression of antibody-mediated allergy and autoimmunity. In contrast, the activating-type Fc receptors (FcRs) are essential for the development of these diseases, suggesting that regulation of inhibitory or activating FcR is an ideal target as a therapeutic agent. In addition, recent crystal structural analyses of FcR-Ig-Fc fragment complexes provide an effective approach for developing FcR-targeting drugs. This review summarises recent advances of FcR, which were mainly obtained by murine studies, and highlights novel antibodies as possible FcR-targeting therapies for allergy, autoimmune diseases and cancer.
KW - Antibody
KW - Antibody-dependent cell-mediated cytotoxicity (ADCC)
KW - Fc receptor (FcR)
KW - FcγR
KW - FcγRIIB
KW - Intravenus immunoglobulin (IVIg)
UR - http://www.scopus.com/inward/record.url?scp=14744305640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14744305640&partnerID=8YFLogxK
U2 - 10.1517/14728222.9.1.169
DO - 10.1517/14728222.9.1.169
M3 - Review article
C2 - 15757489
AN - SCOPUS:14744305640
SN - 1472-8222
VL - 9
SP - 169
EP - 190
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 1
ER -
